Pfizer on Friday reported its third quarter profit for the financial year 2023-24 at Rs 129.98 crore, down 13.7 per cent in comparison to Rs 150.66 crore during the corresponding quarter of previous year. It posted revenue from operations at Rs 539.97 crore, down 13.2 per cent as against Rs 621.75 crore during the third quarter of FY23. The company EBITDA was down 24.9 per cent at Rs 153.4 crore. While the company posted total income at Rs 575.82 crore during Q3FY24, Pfizer’s total expenses during the quarter in review stood at Rs 407.83 crore.
Upon the recommendation of the Nomination and Remuneration Committee, the company board also re-appointed Meena Ganesh as an independent director of the company for a second term of 5 years with effect from March 8, 2024. Meena Ganesh is a PGDM holder from IIM Calcutta and has a graduate degree in Physics from the Madras University. Meena Ganesh serves on the boards of P&G Health & Hygiene Limited, Hitachi Energy and Axis Bank. As the Co-founder & Chairperson, she leads Portea Medical, which she co-founded in July 2013.
Furthermore, it also informed that Satyen Amin, Lead – Market Access has tendered his resignation from employment of the company with effect from March 31, 2024, to pursue an opportunity outside Pfizer Limited. Satyen Amin shall accordingly cease to be a Senior Management Personnel effective the said date.